The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma.
about
Chronic Stress and Glucocorticoids: From Neuronal Plasticity to NeurodegenerationNeuroinflammation in Parkinson's disease and its potential as therapeutic targetRelevance of chronic stress and the two faces of microglia in Parkinson's diseaseNeuroinflammation in the pathophysiology of Parkinson's disease and therapeutic evidence of anti-inflammatory drugsM1 and M2 immune activation in Parkinson's Disease: Foe and ally?Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunityAlkaloids from piper longum protect dopaminergic neurons against inflammation-mediated damage induced by intranigral injection of lipopolysaccharide.The inflammatory transcriptome of reactive murine astrocytes and implications for their innate immune function.The brain dopaminergic system as an important center regulating liver cytochrome P450 in the rat.Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic interventionEvidence of inflammatory system involvement in Parkinson's disease.Cyclopentenone eicosanoids as mediators of neurodegeneration: a pathogenic mechanism of oxidative stress-mediated and cyclooxygenase-mediated neurotoxicity.The endotoxin-induced neuroinflammation model of Parkinson's disease.Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.The acute inflammatory response to intranigral α-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation.Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's diseaseInflammatory Animal Model for Parkinson's Disease: The Intranigral Injection of LPS Induced the Inflammatory Process along with the Selective Degeneration of Nigrostriatal Dopaminergic Neurons.Oxidative stress and microglial cells in Parkinson's diseaseGlucocorticoids: protectors of the brain during innate immune responses.Age and region-specific responses of microglia, but not astrocytes, suggest a role in selective vulnerability of dopamine neurons after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure in monkeys.Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy.A novel synthetic isothiocyanate ITC-57 displays antioxidant, anti-inflammatory, and neuroprotective properties in a mouse Parkinson's disease model.A novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinson's disease induced by MPTP.Central dopaminergic system and its implications in stress-mediated neurological disorders and gastric ulcers: short review.Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease.Enhanced prostacyclin synthesis by adenoviral gene transfer reduced glial activation and ameliorated dopaminergic dysfunction in hemiparkinsonian ratsNeuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic interventionThe lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery.Neuroinflammation in Parkinson's disease.Blockade of Toll-like receptor 4 attenuates morphine tolerance and facilitates the pain relieving properties of morphineRegulator of G-protein signaling 10 promotes dopaminergic neuron survival via regulation of the microglial inflammatory responseAge and duration of inflammatory environment differentially affect the neuroimmune response and catecholaminergic neurons in the midbrain and brainstem.Peripheral inflammation increases the damage in animal models of nigrostriatal dopaminergic neurodegeneration: possible implication in Parkinson's disease incidence.Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson's Disease?The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson's disease: focus on astrocytes.Inflammation in Parkinson's disease: role of glucocorticoids.Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease.The implication of neuronimmunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinson's disease.Sex Differences in Microglia Activity within the Periaqueductal Gray of the Rat: A Potential Mechanism Driving the Dimorphic Effects of Morphine.Relationship Between Obesity, Alzheimer's Disease, and Parkinson's Disease: an Astrocentric View.
P2860
Q26748974-87A72F13-44CD-4CE1-902D-B94B0B5860E9Q26783305-57AB8EBC-75C9-4C7C-916A-DAF2ABA05211Q26796241-04906B54-C56E-466A-9A33-F5E10AD75DC3Q26801035-86AB9028-A48F-4075-A7D5-6119C000C582Q27024667-5A5EBFA7-EFF8-4C13-B8F8-495EDF315C17Q27027973-E7BC1635-AB1C-40D7-8AE0-AC369A939418Q30371352-455922E6-8102-4F77-939A-366A16283B65Q30806520-13104748-CF5C-411C-8585-9AEBD6B5DBBEQ33445762-4FB88870-6107-46B3-ACD3-641A38E999D3Q33663970-50249971-BA75-493D-8140-1F99355603ACQ33890818-FEEAB2CD-7FEA-42C5-AC69-A7989C97089FQ33896920-0B0C247A-9569-471E-9A58-93A5A770F8D0Q34557246-C5649EA8-ED39-431B-AA73-AC2FCB184350Q35589979-BDA8E055-B009-4AB4-857F-81EEA3FEFEA7Q35617879-E6E5C51D-BCE8-46B3-A0EE-8922ECFF8BD4Q35626938-D6870E5C-1468-4E2F-A10C-AAEB90BC5F9FQ35687315-DC0F6104-2B37-4D8A-AD1D-2C3EAEE6BA2FQ35876266-55FFA6F3-3228-40FA-B7D4-C249BE43A9D7Q35943567-AA5D0FDF-8EE3-43E3-B224-E8DBF9351D53Q36072445-91768C2A-90CA-471E-8D13-35EC1511BD0CQ36085162-164DC8AB-4127-40E2-B0F4-AB4749A16041Q36123780-7879A792-8ECF-4802-B1F8-1FC0148ED18BQ36147318-57CAE91F-D36B-4FAB-A158-5E1660144D1AQ36253550-8797C0BB-0B9D-4C87-9CFD-46381703E753Q36537780-2A4FEF3F-D261-4325-A14F-53F592F95D65Q36831055-DA284B20-BD0F-47AB-9308-A421CD58CAC0Q36919403-76629BA3-C5C1-4A8B-BF8B-8B9D64BE35E9Q37076726-2815882D-F363-4E13-85EA-6F7BA0F72CDDQ37079115-35F0DAED-D3E8-4A90-AEC0-B0576C5EE72DQ37208498-31165E02-B5F1-4E9B-85F7-14A0C8758934Q37336951-535ABAF5-0B1A-448A-B1D8-34DC0F04D8DDQ37624173-CDF4BBB6-9AC8-4A6E-8077-702A4D7CD166Q37878282-B5580D6D-ECA6-4AA3-AFAE-48AAEFF3EEECQ38103856-D573E9DA-9BD0-41AC-8C11-AE9C70AF68E1Q38115703-8CA96284-A2DB-4D92-A829-5885D576E8DDQ38425458-1101182F-60A9-4262-B3E0-E368BDAB45CCQ38556918-B3F49F20-2D24-4CFF-AF44-ECE5B6E27D82Q38670012-5DF212C8-56DF-4084-9F91-CFD8D22151D9Q38951157-45A2BADD-3410-4C3A-B880-31922791853CQ38994712-D2A20DCD-1531-4BCA-81D0-51B42EF2BB21
P2860
The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
The degenerative effect of a s ...... alpha, IL-1beta and IFN-gamma.
@en
The degenerative effect of a s ...... alpha, IL-1beta and IFN-gamma.
@nl
type
label
The degenerative effect of a s ...... alpha, IL-1beta and IFN-gamma.
@en
The degenerative effect of a s ...... alpha, IL-1beta and IFN-gamma.
@nl
prefLabel
The degenerative effect of a s ...... alpha, IL-1beta and IFN-gamma.
@en
The degenerative effect of a s ...... alpha, IL-1beta and IFN-gamma.
@nl
P2093
P2860
P921
P1476
The degenerative effect of a s ...... alpha, IL-1beta and IFN-gamma.
@en
P2093
P2860
P304
P356
10.1046/J.1471-4159.2002.00799.X
P407
P577
2002-04-01T00:00:00Z